1-chloro-3-((1S,2S)-2-nitrocyclohexyl)benzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-chloro-3-((1S,2S)-2-nitrocyclohexyl)benzene
• 英文别名: 1-chloro-3-[(1S,2S)-2-nitrocyclohexyl]benzene
• 化学式: C₁₂H₁₄ClNO₂
• 分子量: 239.702
• InChiKey: SEUZKVUYTWQWDC-RYUDHWBXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-chloro-3-((1S,2S)-2-nitrocyclohexyl)benzene 在 盐酸 、 碳酸氢钠 、 溶剂黄146 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 锌 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 4-Aminomethyl-N-((S)-1-{(S)-1-[(1R,2S)-2-(3-chloro-phenyl)-cyclohexylcarbamoyl]-3-methyl-butylcarbamoyl}-ethyl)-benzamide
  参考文献：
  名称：

  CDK2/cyclinA inhibitors: Targeting the cyclinA recruitment site with small molecules derived from peptide leads

  摘要：

  The syntheses of potent small molecule inhibitors of the CDK2/cyclinA recruitment site are described. Structure-activity trends of nanomolar octapeptides were examined through amino-acid substitution and truncation of the sequence resulting in the identification of a smaller, albeit significantly less potent, tetrapeptide lead. These losses in affinity were recovered by side-chain optimization and by rigidification of the peptide backbone using a combination of solid-phase parallel synthesis and structure-based design. Finally, two guanidine functionalities were replaced to improve drug-like properties, resulting in neutral small molecules equal in activity to that of the peptide lead. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.004

文献信息

• CDK2/cyclinA inhibitors: Targeting the cyclinA recruitment site with small molecules derived from peptide leads
  作者：Georgette Castanedo、Kevin Clark、Shumei Wang、Vickie Tsui、Mengling Wong、John Nicholas、Dineli Wickramasinghe、James C. Marsters、Daniel Sutherlin

  DOI：10.1016/j.bmcl.2005.12.004

  日期：2006.3

  The syntheses of potent small molecule inhibitors of the CDK2/cyclinA recruitment site are described. Structure-activity trends of nanomolar octapeptides were examined through amino-acid substitution and truncation of the sequence resulting in the identification of a smaller, albeit significantly less potent, tetrapeptide lead. These losses in affinity were recovered by side-chain optimization and by rigidification of the peptide backbone using a combination of solid-phase parallel synthesis and structure-based design. Finally, two guanidine functionalities were replaced to improve drug-like properties, resulting in neutral small molecules equal in activity to that of the peptide lead. (C) 2005 Elsevier Ltd. All rights reserved.